GGrantIndex
Sort

78,016 grants matching breast cancer

BREAST CANCER SURVIVORS: EXERCISE AND RALOXIFENE

$502,804
Oregon Health And Science University · R01 · FY2002 · NR

Leveraging Sphingolipid Metabolism for Optimal Response of Breast Cancer Cells to Chemotherapy

$502,794
Chiara Luberto · State University New York Stony Brook · P01 · FY2025 · CA

Development of injectable solvent-free tissue-mimetic platform for breast reconstructive surgery

$502,786
Sergei Sheiko · Univ Of North Carolina Chapel Hill · R01 · FY2025 · EB

Development and application of asymmetric-flow field-flow (AF4) technology in fractionation and characterization of exosome subpopulations and novel nanoveiscles in pancreatic cancer model

$502,765
David Charles Lyden · Weill Medical Coll Of Cornell Univ · R01 · FY2019 · CA

Genomic, clinical and behavioral signature of long-term breast cancer survival

$502,763
Loki Natarajan · University Of California, San Diego · R01 · FY2014 · CA

Acoustic Angiography Using Dual-Frequency and Ultrawideband CMUT Arrays

$502,763
Omer Oralkan · North Carolina State University Raleigh · R01 · FY2018 · EB

MYC-regulated RNA Binding Protein Networks and Spliced Isoforms Driving Cancer

$502,751
Olga Anczukow-Camarda · Jackson Laboratory · R01 · FY2025 · CA

HippoPCI Hippocampal Predictors of Cognitive Impairment in Breast Cancer Patients

$502,743
Lei Wang · Northwestern University At Chicago · R01 · FY2012 · NR

Genomics of Human Cancer

$502,725
Cold Spring Harbor Laboratory · R01 · FY2004 · CA

Molecular and biochemical basis of Lymphangioleiomyomatosis

$502,724
John Blenis · Weill Medical Coll Of Cornell Univ · R01 · FY2017 · HL

Molecular and biochemical basis of Lymphangioleiomyomatosis

$502,724
John Blenis · Weill Medical Coll Of Cornell Univ · R01 · FY2016 · HL

Membrane-based immunotherapy for triple negative breast cancer- a partnered approach

$502,655
Periasamy Selvaraj · Emory University · R01 · FY2016 · CA

STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses to hirsutinolides

$502,653
James K Turkson · University Of Hawaii At Manoa · R01 · FY2018 · CA

Australian Breast Cancer Family Registry

$502,630
John L Hopper · University Of Melbourne · U01 · FY2006 · CA

Products of the Transforming Genes of Polyomavirus

$502,618
Brian S Schaffhausen · Dana-Farber Cancer Inst · P01 · FY2007 · CA

Patient Navigation 2.0: Addressing the Challenge of Scaling Navigation through Checklist-based Implementation

$502,590
Melissa A. Simon · Northwestern University At Chicago · R01 · FY2024 · CA

Targeting non-homologous end joining in cancer therapy

$502,557
Ralph Scully · Beth Israel Deaconess Medical Center · RC1 · FY2009 · CA

Targeted Inhibition in Leukemia

$502,537
Nicolas Nassar · Cincinnati Childrens Hosp Med Ctr · R01 · FY2020 · CA

Developmental Funds

$502,500
Eric P Winer · Yale University · P30 · FY2025 · CA

Statistical Genetics of Dose Response Traits

$502,429
Alison Motsinger-Reif · National Institute Of Environmental Health Sciences · ZIA · FY2020 · ES

Breast Cancer, Radiation and the ATM-CHEK2 Pathway

$502,390
Sloan-Kettering Institute For Cancer Res · R01 · FY2005 · CA

Enhancing neoadjuvant chemotherpay responses with targeted T cells

$502,349
Lawrence G Lum · Wayne State University · R01 · FY2011 · CA

Understanding how receptor tyrosine kinase activation dynamics specify proliferative cellular responses

$502,337
Mark A. Lemmon · Yale University · R01 · FY2024 · CA

Therapeutic targeting of autophagy-dependent cancer

$502,312
Andrew M Thorburn · University Of Colorado Denver · R01 · FY2015 · CA

Modeling Response to HER2 target therapies

$502,262
Joe W. Gray · University Of Calif-Lawrenc Berkeley Lab · U54 · FY2011 · CA